Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,123 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (356)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05162352 | Donafenib Plus Sintilimab for Advanced HCC | completed | Phase 2 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03439891 | Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 16 | Robin Kate KelleyOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02421185 | Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 53 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT04511455 | Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment | completed | Phase 2 | 22 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT04522908 | Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function | completed | Phase 2 | 40 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT05431621 | Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers | completed | — | 2,430 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05848947 | SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA(MAApping) | completed | Phase 4 | 5 | Sirtex MedicalINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06799468 | Validation of the TRAIN-AI for the Risk of HCC Recurrence After Liver Transplantation(TRAIN-AI) | completed | — | 1,769 | European Hepatocellular Cancer Liver Transplant GroupOTHER | 0 | Jan 29, 2025 | clinicaltrials |
| NCT04767906 | Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors(CaPture) | completed | Phase 2 | 16 | University of LeipzigOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06776185 | Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma | completed | — | 3,000 | Chen XiaopingOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06760494 | Microvascular Invasion Artificial Intelligence Prediction Via Contrast-enhanced Ultrasound With Explainability(MAPUSE) | completed | — | 250 | Chinese PLA General HospitalOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03756051 | Harms of Hepatocellular Carcinoma Surveillance | completed | — | 2,871 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04802954 | Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients(STARHE) | completed | N/A | 400 | IHU StrasbourgOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT01640522 | Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms(CaSSY) | completed | N/A | 261 | University of PittsburghOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT02528643 | A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 165 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Dec 6, 2024 | clinicaltrials |
| NCT06683820 | Triple Recipient Strategy Using Split, Domino, and Auxiliary Techniques | completed | — | 3 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT03009461 | Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis | completed | Phase 2 | 64 | Peking UniversityOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04701060 | Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | completed | Phase 2 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04340193 | A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer(CheckMate 74W) | completed | Phase 3 | 26 | Bristol-Myers SquibbINDUSTRY | 19 | Nov 26, 2024 | clinicaltrials |
| NCT02143401 | Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2024 | clinicaltrials |
| NCT00059267 | Prevention of Recurrent Hepatitis B After Liver Transplantation | completed | — | 317 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Nov 15, 2024 | clinicaltrials |
| NCT03268499 | Emulsion Versus Suspension in Chemoembolization for Hepatocellular Carcinoma | completed | N/A | 80 | Chinese University of Hong KongOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT03606590 | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | completed | Phase 2 | 25 | NovoCure Ltd.INDUSTRY | 6 | Nov 14, 2024 | clinicaltrials |
| NCT04313868 | GEN2 Directed Cancer Immunotherapy Trial(GEN2) | completed | Phase 1 | 61 | GenVivo, Inc.INDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05003700 | Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma | completed | Phase 2 | 39 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04954794 | TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02) | completed | Phase 2 | 29 | Fudan UniversityOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06663904 | Different Abbreviated MRI for Hepatocellular Carcinoma Diagnosis(AMRI; LIRADS) | completed | — | 938 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03419897 | Study of BGB-A317 in Participants With Previously Treated Unresectable HCC | completed | Phase 2 | 249 | BeiGeneINDUSTRY | 8 | Oct 26, 2024 | clinicaltrials |
| NCT02511522 | Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases | completed | N/A | 66 | Canadian Cancer Trials GroupNETWORK | 1 | Oct 23, 2024 | clinicaltrials |
| NCT02325739 | FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | completed | Phase 1 / Phase 2 | 172 | Novartis PharmaceuticalsINDUSTRY | 11 | Oct 21, 2024 | clinicaltrials |
| NCT06637059 | Artificially Intelligent Model for Accurate Detection of HCC | completed | — | 1,092 | Zhejiang UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04011033 | Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC | completed | Phase 2 | 60 | Beijing YouAn HospitalOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06629857 | A Cross Sectional Study Evaluating the Mean Levels of Alpha Fetoprotein in Patients of Hepatocellular Carcinoma and Its Correlates in Pakistan | completed | — | 94 | Darul Sehat HospitalOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03253289 | Meclizine for Hepatocellular Carcinoma(OPTIM) | completed | Phase 1 | 13 | Tannaz ArmaghnayOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06621485 | Calculator Predicts Early Mortality Post Hepatocellular Carcinoma Resection | completed | — | 4,966 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT05221398 | Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma | completed | — | 517 | Guangxi Medical UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT03175679 | Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC | completed | Phase 1 | 10 | Beijing YouAn HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04310540 | PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer | completed | Early Phase 1 | 42 | Mayo ClinicOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04401813 | Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma | completed | Phase 1 | 97 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | completed | Phase 2 | 156 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 4, 2024 | clinicaltrials |
| NCT03299946 | Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT04170556 | Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)(GOING) | completed | Phase 1 / Phase 2 | 69 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT01906216 | Sorafenib Chemoembolization Evaluation Controlled Trial(SELECT) | completed | Phase 3 | 199 | Air Force Military Medical University, ChinaOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT01752933 | SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 52 | Astex Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 27, 2024 | clinicaltrials |
| NCT02112656 | Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)(OPTIMA) | completed | Phase 3 | 554 | ImunonINDUSTRY | 14 | Aug 20, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 17, 2025source: clinicaltrials